Canine immune-mediated hemolytic anemia: Treatment and prognosis

Compendium: Continuing Education For Veterinarians

Volumn 29, Issue 4, 2007, Pages 230-239

  Balch, Andrea ^a   Mackin, Andrew ^b  

^a Las Vegas Veterinary Referral Center   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AGE; ANIMAL; ANIMAL DISEASE; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION; DOG; DOG DISEASE; PATHOLOGY; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SPLENECTOMY; TREATMENT OUTCOME;

AGE FACTORS; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; BLOOD TRANSFUSION; DOG DISEASES; DOGS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; RISK FACTORS; SEX FACTORS; SPLENECTOMY; TREATMENT OUTCOME;

EID: 34249299785     PISSN: 19408307     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Burgess K, Moore A, Rand W, et al: Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide. J Vet Intern Med 14(4): 456-462, 2000.
2. Scott-Moncrieff JC, Treadwell NG, McCullough SM, et al: Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. JAAHA 37(3):220-227, 2001.
3. Miller SA, Hohenhaus AE, Hale AS: Case-control study of blood type, breed, sex, and bacteremia in dogs with immune-mediated hemolytic anemia. JAVMA 224(2):232-235, 2004.
4. Carr AP, Panciera DL, Kidd L: Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 cases. J Vet Intern Med 16(5):504-509, 2002.
5. Stokol T, Blue J, French T: Idiopathic pure red cell aplasia and nonregenerative immune-mediated anemia in dogs: 43 cases (1988-1999). JAVMA 216(9):1429-1436, 2000.
6. Weinkle TK, Center SA, Randolph JF, et al: Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). JAVMA 226(11):1869-1880, 2005.
7. Klein MK, Dow S, Rosychuk R: Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: Ten cases (1982-1987). ~JAVMA 195(2):246-250, 1989.
8. Grundy S, Barton C: Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). JAVMA 218(4):543-546, 2001.
9. Day TK, Macintire DK, Murtaugh RJ, et al: Differing opinions on treatment of immune-mediated hemolytic anemia. JAVMA 218(9):1414-1415, 2001.
10. Melzer KJ, Wardrop KJ, Hale AS, et al: A hemolytic transfusion reaction due to DEA 4 alloantibodies in a dog. J Vet Intern Med 17(6):931-933, 2003.
11. Plumb D: Veterinary Drug Handbook, ed 4. Ames, Iowa State University Press, 2002.
12. McCullough S: Immune-mediated hemolytic anemia: Understanding the nemesis. Vet Clin Small Anim 33:1295-1315, 2003.
13. Reimer ME, Troy GC, Warnick LD: Immune-mediated hemolytic anemia: 70 cases (1988-1996).JAAHA 35(5):384-390, 1999.
14. Mason N, Duval D, Shofer FS, et al: Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune mediated hemolytic anemia in dogs: A randomized controlled clinical trial. J Vet Intern Med 17(2):206-212, 2003.
15. Klag A, Giger U, Shofer F: Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). JAVMA 202(5):783-788, 1993.
16. Giger U: Regenerative anemias caused by blood loss or hemolysis, in Ettinger SJ, Feldman EC (eds): Textbook of Veterinary Internal Medicine, ed 6. St Louis, WB Saunders, 2005, pp 1886-1907.
17. Allenspach K, Rüfenacht S, Sauter S, et al: Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J Vet Intern Med 20(2):239-244, 2006.
18. Patricelli AJ, Hardie RJ, McAnulty JE: Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. JAVMA 220(7):1009-1016, 2002.
19. Adamo FP, O'Brien RT: Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. JAVMA 225(8):1211-1216, 2004.
20. O'Neill T, Edwards GA, Holloway S: Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. J Small Anim Pract 45(5):238-243, 2004.
21. Reagan WJ, Scott-Moncrieff C, Christian J, et al: Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res 59(12):1568-1574, 1998.
22. Scott-Moncrieff JC, Reagan Wf, Snyder PW, et al: Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. JAVMA 210(11):1623-1627, 1997.
23. Scott-Moncrieff JC, Reagan W: Human intravenous immunoglobulin therapy. Sam Vet Med Surg (Small Anim) 12(3):178-185, 1997.
24. nd Annu Forum Am Coll Vet Intern Med:326-327, 2004.
25. th Annu Forum Am Coll Vet Intern Med:438-439, 1998.
26. Banyard MRC, Hassett RS: The use of mycophenolate mofetil in the treatment of a case of immune-mediated glomerulonephritis in a dog. Aust Vet Pract 31:103-106, 2001.
27. Charney SC, Bergman PJ, Hohenhaus AE, et al: Risk factors for sterile hemorrhagic cystitis in dogs with lymphoma receiving cyclophosphamide with or without concurrent administration of furosemide: 216 cases (1990-1996). JAVMA 222(10):1388-1393, 2003.
28. Feldman B, Handagama P, Lubberink A: Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. JAVMA 187(6):617-619, 1985.
29. Toll J, Aronsohn M: Prospective evaluation of medical therapy with or without splenectomy for the treatment of severe immune mediated hemolytic anemia [abstract]. J Vet Intern Med 17(3):383, 2003.
30. McManus P, Craig L: Correlation between leukocytosis and necropsy findings in dogs with immune mediated hemolytic anemia: 34 cases (1994-1999).JAVMA 4218(8):1308-1313, 2001.
31. Weiss DJ, Brazzell JL: Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 20(3):682-686, 2006.
32. Feldman BF, Madewell BR, O'Neill S: Disseminated intravascular coagulation: Antithrombin, plasminogen and coagulation abnormalities in 41 dogs. JAVMA 179:151-154, 1999.
33. Thompson MF, Scott-Moncrieff JC, Brooks MB: Effect of a single plasma transfusion on thromboembolism in 13 dogs with primary immune-mediated hemolytic anemia. JAAHA 40(6):446-454, 2004.
34. Rozanski E: Management of the hyper-coagulable patient; anticoagulant therapy. Proc Tufts Anim Expo:221, 2002.
35. Dunn M, Charland V, Thorneloe C: The use of a low molecular weight heparin in 6 dogs [abstract]. J Vet Intern Med 18(3):389, 2004.
36. Lunsford K, Mackin A, Langsten C, et al: Pharmacokinetics of the biological effects of subcutaneous enoxaparin in dogs [abstract], J Vet Intern Med 19(3):400, 2005.
37. Duval D, Giger U: Vaccine associated immune mediated hemolytic anemia in the dog. J Vet Intern Med 10(5):290-295, 1996.
38. Whelan MF, Rozanski EA, O'Tolle TE, et al: Use of the canine hemolytic anemia objective score (CHAOS) to predict survival in dogs with immunemediated hemolytic anemia [abstract]. J Vet Intern Med 20(3):714, 2006.